Melanotan II vs PT-141 at a glance
| Parameter | Melanotan II (MT-II) | PT-141 (bremelanotide) |
|---|---|---|
| Origin | University of Arizona, Hruby lab, 1980s | Derived from the MT-II pharmacophore by Palatin Technologies |
| Structure | Cyclic heptapeptide, alpha-MSH analogue | Cyclic heptapeptide, alpha-MSH analogue |
| Receptor selectivity | Nonselective agonist, MC1R through MC5R | Selective agonist at MC3R and MC4R |
| Skin pigmentation effect | Pronounced, via MC1R agonism | Minimal; hyperpigmentation reported with repeated dosing |
| Furthest clinical stage | Phase 2 (ED trial, n=10) | Phase 3 complete (RECONNECT, n=1,267) |
| Regulatory status | Never submitted for approval | FDA approved as Vyleesi, June 21, 2019 |
| Approved indication | None | HSDD in premenopausal women |
| Dominant adverse effect | Nausea | Nausea, reported in 40% of RECONNECT participants |
What links Melanotan II and PT-141
Victor Hruby's medicinal chemistry group at the University of Arizona synthesized Melanotan II in the 1980s as a cyclic, metabolically stabilized version of alpha-melanocyte-stimulating hormone (alpha-MSH). The design substituted norleucine for methionine at position 4 and D-phenylalanine for L-phenylalanine at position 7, then closed the chain into a ring. Hadley and colleagues documented the chemistry and the compound's early trial history in a 1998 review (Hadley et al., Pharm Biotechnol 1998;11:575-95, PMID 9760697).
MT-II was developed for photoprotective tanning, but volunteers in those studies reported spontaneous erections during dosing. That side observation redirected research toward the melanocortin system's role in sexual arousal, and Palatin Technologies later isolated a shorter pharmacophore from the same scaffold to build bremelanotide, the compound now known as PT-141. The two peptides share a common ancestor and overlapping chemistry, but they were engineered toward different receptor targets, and the research literature reflects that split.
The full development history of each compound is covered separately: Melanotan II research overview and PT-141 (bremelanotide) research overview.
Receptor pharmacology: nonselective vs targeted
Alpha-MSH and its analogues act through five G protein-coupled melanocortin receptor subtypes, MC1R through MC5R, all coupled to Gs and cyclic AMP signaling. MT-II is nonselective. It engages all five subtypes at meaningful affinity, which is why its trial data shows effects spanning pigmentation, appetite, and sexual arousal at once.
PT-141 was engineered to narrow that footprint. It behaves as a selective agonist at MC3R and MC4R, both concentrated in the central nervous system rather than the skin. A 2003 review in Expert Opinion on Investigational Drugs (Diamond et al., PMID 12851303) traced this receptor mapping using c-Fos activation studies in rodent hypothalamic tissue.
MC3R density peaks in the arcuate nucleus; MC4R is distributed across the hypothalamus, thalamus, and hippocampus. Because PT-141 largely spares MC1R, the tanning effect that defines MT-II's profile is not a consistent finding with bremelanotide, though hyperpigmentation has been reported after repeated dosing in some participants.
Clinical evidence: Phase 2 vs Phase 3
The clinical record for the two compounds is not close to symmetrical. MT-II's largest published trial was a tanning study: 28 healthy men received 10 subcutaneous injections over 12 days, with skin darkening confirmed against placebo (p<0.001) (Levine et al., JAMA 1991;266:2730-6, n=28, PMID 1658407). Its erectile dysfunction data is smaller still: a 10-man, double-blind, placebo-controlled crossover trial in which 8 of 10 subjects developed clinically apparent erections after subcutaneous MT-II at 0.025 mg/kg, with mean tip rigidity above 80% lasting 38.0 minutes versus 3.0 minutes for placebo (p=0.0045) (Wessells et al., J Urol 1998;160:389-93, PMID 9679884). No sponsor carried MT-II past Phase 2.
PT-141's early data came from an intranasal formulation in men, which showed a dose-dependent erectile response above 7 mg (Rosen et al., PMID 14963471), but blood pressure signals ended that route. Palatin Technologies reformulated the compound as a subcutaneous injection and shifted the target indication to hypoactive sexual desire disorder (HSDD) in women, then ran the RECONNECT program: two Phase 3 randomized, double-blind, placebo-controlled trials registered at NCT02333071 and NCT02338960, enrolling 1,267 premenopausal women over 24 weeks. Kingsberg and colleagues reported improvements of 0.35 points on the Female Sexual Function Index desire domain and a 0.33-point reduction in sexual distress scores, both p<0.001 (Kingsberg et al., Obstet Gynecol 2019, PMID 31599840). The FDA approved bremelanotide as Vyleesi on June 21, 2019, under NDA 210557.
Safety data compared
Nausea dominates the adverse event profile for both compounds, consistent with melanocortin receptor activity in the brainstem's emesis-regulating nuclei. In the Wessells MT-II trial, nausea was transient and did not require treatment in any subject. In the RECONNECT program, nausea was reported by 40% of participants, with flushing at 20.6%, injection site reactions at 13%, and headache at 12% (Simon et al., 2019, PMC6819023); a 52-week open-label extension showed no new safety signals.
Blood pressure increases appear with both compounds at sufficient dose. MT-II trials above the published research doses documented rises in blood pressure, and Palatin's own intranasal PT-141 formulation showed a large enough systolic effect that the company abandoned that route entirely. The subcutaneous PT-141 dose approved as Vyleesi still carries an FDA label warning for transient systolic and diastolic increases of roughly 6 to 7 mmHg within 12 hours of dosing, typically resolving by the next day.
Practical considerations for researchers
Both compounds are lyophilized peptides that follow the same reconstitution and storage principles as the rest of the catalog. See the peptide reconstitution guide for bacteriostatic water handling, and the lyophilized peptide storage guide for cold-chain and shelf-life data relevant to Indonesia's tropical climate, where ambient heat and humidity accelerate degradation once a vial leaves cold storage. Researchers converting mg/kg trial protocols into solution volumes for in-model work can use the dosing calculator as a reference tool.
Neither compound has an approved human dosing protocol outside the narrow Vyleesi indication, and the RECONNECT dose (1.75 mg subcutaneous, as needed) applies specifically to that population and formulation. Published research doses for MT-II and the earlier PT-141 trials are protocol data from the literature, not clinical guidance, and both compounds remain outside general medical use in every market where Zurich Biotech ships. The full compound catalog is at /#compounds.